Abstract: A semiconductor laser device includes: semiconductor laser arrays; collimating members; a condenser lens provided, in common, for collimated light beam arrays outputted from the respective collimating members, and including a light incident surface on which a light incident row pattern including light incident regions is formed through entering of the collimated light beam arrays; and an optical fiber. A condenser lens incident optical path length of at least one of the semiconductor laser arrays is different from that of any other one of the semiconductor laser arrays. A collimated light beam array derived from one of the semiconductor laser arrays that corresponds to the largest condenser lens incident optical path length is directed to a predetermined light incident region in the light incident surface. The predetermined light incident region is other than the outermost light incident region in the light incident row pattern.

Abstract: A semiconductor laser device includes: semiconductor laser arrays; collimating members; a condenser lens provided, in common, for collimated light beam arrays outputted from the respective collimating members, and including a light incident surface on which a light incident row pattern including light incident regions is formed through entering of the collimated light beam arrays; and an optical fiber. A condenser lens incident optical path length of at least one of the semiconductor laser arrays is different from that of any other one of the semiconductor laser arrays. A collimated light beam array derived from one of the semiconductor laser arrays that corresponds to the largest condenser lens incident optical path length is directed to a predetermined light incident region in the light incident surface. The predetermined light incident region is other than the outermost light incident region in the light incident row pattern.

Abstract: Disclosed is a semiconductor laser optical device that can suppress the occurrence of crosstalk light to obtain high collimating efficiency and is relatively inexpensive and compact. This semiconductor laser optical device includes: a laser source that includes a semiconductor laser element; a first collimator lens that is provided on a laser light emission side of the laser source and collimates a light component diverging in a fast-axis direction of laser light emitted from the laser source; and a second collimator lens that is provided on an emission side of the first collimator lens and collimates a light component diverging in a slow-axis direction of light emitted from the first collimator lens. The first collimator lens has a function of making light of which spreading in the slow-axis direction is suppressed incident on the second collimator lens.

Abstract: In a discharge lamp lighting apparatus comprising a short arc type discharge lamp and a power supply unit, a relation of the natural frequency fe (Hz) of the electrodes, the ripple frequency fd (Hz) of the alternating current that is supplied to the discharge lamp, and the ripple power Pr (W) of the alternating current, satisfies a formula: Pr ? ? f e - f d ? · ( - 0.13 × Vh Va + 3.0 ) , wherein the volume of the electrode head portion is represented as Vh and the volume of the segment of the electrode axis portion that projects into the arc tube is represented as Va. When the alternating current supplied to the discharge lamp satisfies the formula, it is possible to prevent or control damage in the electrode axis portion, since vibration produced in the electrodes during lighting of the discharge lamp is small even if the discharge lamp is lighted for a long time.

Abstract: A high pressure discharge lamp has an electric discharge container with sealing portions formed at both ends of a light emission section, and electrodes made of tungsten. The electrode has a base end which is buried in the sealing portion. Tips of the electrodes face each other in the light emission section. Purity of the tungsten is 99.99% or more. The electrode has a large diameter portion formed at the tip of the electrode and an axis portion whose diameter is smaller than that of the large diameter portion. A part of a surface of the large diameter portion has a concavo-convex structure where a portion having grooves in a circumference direction and a portion having no groove are asymmetrically formed with respect to an axis of the electrode.

Abstract: [PROBLEMS] Provided is a compound which has an antagonistic action on a muscarinic M3 receptor and is useful as an active ingredient of a prophylactic and/or therapeutic agent for an inflammatory disease such as a chronic obstructive pulmonary disease (COPD), asthma and the like. [MEANS For SOLVING PROBLEMS] The present inventors have made studies on a compound having an antagonistic action on the binding of a muscarinic M3 receptor, and they have found that an aza-bridged-ring compound or a salt thereof has an antagonistic action on the binding of a muscarinic M3 receptor, thereby completing the present invention. The aza-bridged-ring compound of the present invention has an antagonistic action on the binding of a muscarinic M3 receptor, and can be used as a prophylactic and/or therapeutic agent for an inflammatory disease such as a chronic obstructive pulmonary disease (COPD), asthma and the like.

Abstract: In a discharge lamp lighting apparatus comprising a short arc type discharge lamp and a power supply unit, a relation of the natural frequency fe (Hz) of the electrodes, the ripple frequency fd (Hz) of the alternating current that is supplied to the discharge lamp, and the ripple power Pr (W) of the alternating current, satisfies a formula: Pr ? ? f e - f d ? · ( - 0.13 × Vh Va + 3.0 ) , wherein the volume of the electrode head portion is represented as Vh and the volume of the segment of the electrode axis portion that projects into the arc tube is represented as Va. When the alternating current supplied to the discharge lamp satisfies the formula, it is possible to prevent or control damage in the electrode axis portion, since vibration produced in the electrodes during lighting of the discharge lamp is small even if the discharge lamp is lighted for a long time.

Abstract: To provide a compound which has an excellent activity to modulate the functions of CCR4 or TARC and/or MDC and can be used for the prevention and/or treatment of various inflammatory diseases, allergic diseases, autoimmune diseases and the like. An acylaminopiperidine compound represented by the formula (I) or a pharmaceutically acceptable salt thereof. [Symbols in the formula represent the following meanings; A: a single bond or C1-C6 alkylene, R1: phenyl which may be substituted, etc., R2: —H or C1-C6 alkyl, R3: —H, C1-C6 alkyl or C3-C8 cycloalkyl, R4: pyrrolidin-2-yl which may be substituted, etc., and D: benzene ring or pyrazole ring].

Abstract: A high pressure discharge lamp has an electric discharge container with sealing portions formed at both ends of a light emission section, and electrodes made of tungsten. The electrode has a base end which is buried in the sealing portion. Tips of the electrodes face each other in the light emission section. Purity of the tungsten is 99.99% or more. The electrode has a large diameter portion formed at the tip of the electrode and an axis portion whose diameter is smaller than that of the large diameter portion. A part of a surface of the large diameter portion has a concavo-convex structure where a portion having grooves in a circumference direction and a portion having no groove are asymmetrically formed with respect to an axis of the electrode.

Abstract: [Problems] Provided is a compound which has an antagonistic action on a muscarinic M3 receptor and is useful as an active ingredient of a prophylactic and/or therapeutic agent for an inflammatory disease such as a chronic obstructive pulmonary disease (COPD), asthma and the like. [Means for Solving Problems] The present inventors have made studies on a compound having an antagonistic action on the binding of a muscarinic M3 receptor, and they have found that an aza-bridged-ring compound or a salt thereof has an antagonistic action on the binding of a muscarinic M3 receptor, thereby completing the present invention. The aza-bridged-ring compound of the present invention has an antagonistic action on the binding of a muscarinic M3 receptor, and can be used as a prophylactic and/or therapeutic agent for an inflammatory disease such as a chronic obstructive pulmonary disease (COPD), asthma and the like.

Abstract: Optical apparatus with a discharge lamp and a concave reflecting mirror, the concave reflecting mirror has a front elliptical reflecting mirror portion, a middle spherical reflecting mirror portion, and a rear elliptical reflecting mirror portion; the relationship between an angle ? between a virtual tangential line VTL, which runs from the center position between the electrodes to the outer surface of the electrode positioned towards the neck of the concave reflecting mirror, and the beam axis Z and an angle ? between a virtual straight line VSL, which runs from the center position between the electrodes to the boundary position between the middle spherical reflecting mirror portion and the rear elliptical reflecting mirror portion, and the beam axis Z is ?>?; and the relationship between the volume V of the electrode E1 (mm3) and the wattage (P) meets the condition, 0.07×EXP(0.014×P)<V.

Abstract: [Problem] To provide a compound which has an excellent activity to modulate the functions of CCR4 or TARC and/or MDC and can be used for the prevention and/or treatment of various inflammatory diseases, allergic diseases, autoimmune diseases and the like. [Means for Resolution] An acylaminopiperidine compound represented by the formula (I) or a pharmaceutically acceptable salt thereof. [Symbols in the formula represent the following meanings; A: a single bond or C1-C6 alkylene, R1: phenyl which may be substituted, etc., R2: —H or C1-C6 alkyl, R3: —H, C1-C6 alkyl or C3-C8 cycloalkyl, R4: pyrrolidin-2-yl which may be substituted, etc., and D: benzene ring or pyrazole ring].

Abstract: A pyridazinone derivative compound shown by the following formula (I): wherein R1 is selected from hydrogen, etc.; R2 is selected from substituted or unsubstituted aryl, etc.; R3 is hydrogen, etc.; p is 0, 1 or 2; R4 and R5, are each hydrogen, etc.; R6 and R7, are taken together to form a group of the formula: wherein R8 is hydrogen; X is selected from oxygen, etc; R10 is selected from hydrogen, etc.; R11 is selected from hydrogen, etc.; R12 is selected from hydrogen, etc.; R13 is selected from hydrogen, etc.; R14 is selected from hydrogen, etc.; m and n are each 0, 1, or 2, or a pharmaceutically acceptable salt thereof, which is useful as a medicament.

Abstract: There is provided a pharmaceutical drug, particularly a novel compound useful for prophylaxis or a therapeutic treatment of various diseases involving infections with viruses of the herpesvirus family, specifically various herpesvirus infections such as varicella (chicken pox) via varicella zoster virus, varicella zoster via recurrent infection with latent varicella zoster virus, herpes labialis and herpes encephalitis via HSV-1 and genital herpes via HSV-2 infection. An N-{2-[(4-substituted phenyl)amino]-2-oxoethyl}tetrahydro-2H-thiopyran-4-carboxamide derivative, of which phenyl group is substituted at position 4 with a specific 5- or 6-membered heteroaryl group, and a salt thereof have an effective anti-virus activity, and the oral administration thereof at a low dose enabled the therapeutic treatment of the above diseases.

Abstract: To provide an optical apparatus that can use a lamp's radiant energy efficiently and that is suited to demands for smaller size.

Abstract: There is provided a pharmaceutical drug, particularly a novel compound useful for prophylaxis or a therapeutic treatment of various diseases involving infections with viruses of the herpesvirus family, specifically various herpesvirus infections such as varicella (chicken pox) via varicella zoster virus, varicella zoster via recurrent infection with latent varicella zoster virus, herpes labialis and herpes encephalitis via HSV-1 and genital herpes via HSV-2 infection. An N-{2-[(4-substituted phenyl)amino]-2-oxoethyl}tetrahydro-2H-thiopyran-4-carboxamide derivative, of which phenyl group is substituted at position 4 with a specific 5- or 6-membered heteroaryl group, and a salt thereof have an effective anti-virus activity, and the oral administration thereof at a low dose enabled the therapeutic treatment of the above diseases.

Abstract: The invention relates to a novel amide derivative which is an N-({[4-(substituted thiazol-4-yl)phenyl]carbamoyl}methyl)amide derivative having a characteristic in that an aryl or heteroaryl group as an aromatic ring group is directly substituted on the N atom of amido group. Since said amide derivative has excellent anti-herpesvirus action, it is useful as medicaments and antiviral agents, particularly as preventive or therapeutic agents for various diseases accompanied by Herpesviridae virus infections, illustratively, varicella (chickenpox) accompanied by varicella zoster virus infection, shingles accompanied by the recurrent infection of latent varicella zoster virus, labial herpes and herpes encephalitis accompanied by HSV-1 infection, genital herpes accompanied by HSV-2 and the like various herpesvirus infections.

Abstract: A pharmaceutical drug, particularly a novel compound useful for the prophylaxis or therapeutic treatment of various diseases involving infections with viruses of the Herpesviridae family, specifically various herpesvirus infections such as varicella (chicken pox) via varicella zoster virus, varicella zoster via recurrent infection with latent varicella zoster virus, herpes labialis and herpes encephalitis via HSV-1 and genital herpes via HSV-2 infection. N-{2-[(4-Substituted phenyl)amino]-2-oxoethyl}tetrahydro-2H-thiopyran-4-carboxamide derivative where the phenyl group is substituted at position 4 with a specific five-membered or 6-membered heteroaryl group, has such great anti-virus activity that the oral dosing thereof at a low dose enabled the therapeutic treatment of the diseases.

Abstract: A pharmaceutical drug, particularly a novel compound useful for the prophylaxis or therapeutic treatment of various diseases involving infections with viruses of the Herpesviridae family, specifically various herpesvirus infections such as varicella (chicken pox) via varicella zoster virus, varicella zoster via recurrent infection with latent varicella zoster virus, herpes labialis and herpes encephalitis via HSV-1 and genital herpes via HSV-2 infection. N-{2-[(4-Substituted phenyl)amino]-2-oxoethyl}tetrahydro-2H-thiopyran-4-carboxamide derivative where the phenyl group is substituted at position 4 with a specific five-membered or 6-membered heteroaryl group, has such great anti-virus activity that the oral dosing thereof at a low dose enabled the therapeutic treatment of the diseases.

Abstract: The invention relates to a novel amide derivative which is an N-({[4-(substituted thiazol-4-yl)phenyl]carbamoyl}methyl)amide derivative having a characteristic in that an aryl or heteroaryl group as an aromatic ring group is directly substituted on the N atom of amido group. Since said amide derivative has excellent anti-herpesvirus action, it is useful as medicaments and antiviral agents, particularly as preventive or therapeutic agents for various diseases accompanied by Herpesviridae virus infections, illustratively, varicella (chickenpox) accompanied by varicella zoster virus infection, shingles accompanied by the recurrent infection of latent varicella zoster virus, labial herpes and herpes encephalitis accompanied by HSV-1 infection, genital herpes accompanied by HSV-2 and the like various herpesvirus infections.